SanaGen was recently granted a Eurostars Grant, together with Sanquin Research and the Swiss Biotech company InSphero. The objective of this project is to develop a breakthrough gene therapy, to “cure” severe Alpha-1 anti-Trypsin Deficiency (AATD). SanaGen is recruiting a research technician for this project.

Team

Together with the lead scientist you will form the research team of SanaGen. The project will be executed in close collaboration with consortium partners Sanquin and InSphero.

Prof. dr. Jan Voorberg, head of the Molecular and Cellular Hemostasis research group at Sanquin, is an internationally recognized expert in the field of bleeding disorders who has extensively studied rare bleeding disorders such as hemophilia and other blood clotting factor deficiencies.

InSpero has developed one of the best-in-class 3D liver-spheroid platforms for drug discovery (e.g., diet-induced steatosis, NASH) and toxicology.

Together with the lead scientist from SanaGen, you will be working on the development of AAV mediated gene therapy for AATD, mainly focusing on optimization of the AAV-delivered transgene, capsid optimization and validation of the candidates in in vivo models.

Qualifications

You have experience with molecular biological techniques, including plasmid cloning, cell culture, plasmid transfections and PCR. Experience with the production of adeno-associated viral vectors and working with laboratory animals would be an asset.

What we offer

The position involves a temporary appointment for at least 1 year, 32-36 hours/week. Location Amsterdam.  Starting date: 1 april 2024.

Depending on education and relevant work experience a competitive gross monthly salary with 8% holiday allowance and 8% end-of-year bonus.

Interested?

Evaluation of candidates will begin immediately, and continue until the position is filled. For any questions or to immediately apply, please send an application letter and CV by email to:

Dr. Rachel van Beem, COO

SanaGen B.V.

rachel@sana-gen.com

+31654953811